Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
about
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so farNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceAfatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?
P2860
Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Afatinib in first-line setting ...... iminary results of LUX-Lung 7?
@en
Afatinib in first-line setting ...... iminary results of LUX-Lung 7?
@nl
type
label
Afatinib in first-line setting ...... iminary results of LUX-Lung 7?
@en
Afatinib in first-line setting ...... iminary results of LUX-Lung 7?
@nl
prefLabel
Afatinib in first-line setting ...... iminary results of LUX-Lung 7?
@en
Afatinib in first-line setting ...... iminary results of LUX-Lung 7?
@nl
P2093
P2860
P356
P1476
Afatinib in first-line setting ...... iminary results of LUX-Lung 7?
@en
P2093
Alessia Pochesci
Chiara Catania
Cristina Noberasco
Ester Del Signore
Filippo de Marinis
Gianluca Spitaleri
P2860
P304
P356
10.21037/JTD.2016.02.21
P577
2016-03-01T00:00:00Z